The NHS is set to introduce a groundbreaking weight loss jab called tirzepatide for patients with type 2 diabetes. Around 180,000 individuals with the condition who cannot tolerate metformin will be eligible for the once-weekly injection. The National Institute for Health and Care Excellence (Nice) has recommended tirzepatide as a diabetic medication to be used in conjunction with diet and exercise. Subject to supply availability from pharmaceutical company Eli Lilly, it could be available as early as October.
Tirzepatide, sold under the brand name Mounjaro, has been approved for use for diabetics in the NHS
The above graphic shows how weight-loss drug tirzepatide works. It works to suppress hunger by mimicking hormones indicating that the body is full. It also shows the passage of food through the stomach by reducing the production of stomach acid and contractions of the muscle
In addition to treating diabetes, tirzepatide is also being evaluated for its potential benefits in weight loss. As a GLP-1 agonist, the drug helps suppress appetite and reduce food intake. Clinical trials have shown that it also boosts insulin production and leads to significant weight loss in type 2 diabetes patients. In fact, after just one year of use, more than 20% of patients had lost a substantial amount of weight. Experts have even compared tirzepatide to other weight loss drugs and hailed it as highly effective. Nice’s approval comes after careful consideration of the drug’s efficacy in treating type 2 diabetes, which affects nearly two-thirds of patients who have difficulties managing their blood sugar levels. This groundbreaking medication offers hope for better control of the condition and improved health outcomes.
Given the increasing demand for weight loss treatments, tirzepatide’s availability as a weight loss aid is eagerly awaited. Initial indications are that it may be even more potent than its closest rival Wegovy, which was recently approved for weight loss treatment. Danish firm Novo Nordisk produces Wegovy and tirzepatide, along with other weight loss drugs like Liraglutide and Orlistat, are expected to make a significant impact on obesity treatment within the healthcare sector.
Trials suggest tirzepatide is marginally more powerful than its rival Wegovy when it comes to weight loss. Produced by Danish firm Novo Nordisk Wegovy was recently approved for use on the NHS. Liraglutide and Orlistat are other weight loss drugs to treat obesity already in use in the health service
The popularity of tirzepatide as a weight loss aid has caused a shortage of diabetic medication Ozempic, which contains the same key ingredient. The NHS issued a notice to stop off-label prescribing of Ozempic due to limited stocks. In the current landscape of disrupted drug supplies, the introduction of tirzepatide is welcome news. David Webb, the chief pharmaceutical officer at NHS England, expressed his enthusiasm for the new treatment, stating that it will greatly improve the lives of individuals with type 2 diabetes and provide them with the chance of a healthier future.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
